Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Astria Therapeutics ( (ATXS) ) has issued an announcement.
Astria Therapeutics, Inc. has amended its 2022 Inducement Stock Incentive Plan to increase the shares of common stock reserved for issuance from 1,700,000 to 2,800,000. This amendment, made without stockholder approval, aims to attract new talent by offering stock awards to individuals not previously employed by the company, potentially strengthening its workforce and aligning employee interests with those of shareholders.
More about Astria Therapeutics
Astria Therapeutics, Inc. operates in the biotechnology industry, focusing on developing therapies to address unmet medical needs.
YTD Price Performance: 21.88%
Average Trading Volume: 339,206
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $528.2M
For a thorough assessment of ATXS stock, go to TipRanks’ Stock Analysis page.